The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration - a phase IV randomised clinical trial with ranibizumab: the FLUID study-Reference-Cited by-同舟云学术

The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration - a phase IV randomised clinical trial with ranibizumab: the FLUID study

Published:2016-03-24 Issue:1 Volume:16 Page:
ISSN:1471-2415
Container-title:BMC Ophthalmology
language:en
Short-container-title:BMC Ophthalmol

Author:

Arnold Jennifer J.,Markey Caroline M.,Kurstjens Nicol P.,Guymer Robyn H.

Funder

Novartis Pharmaceuticals Australia Pty Ltd

Publisher

Springer Science and Business Media LLC

Subject

Ophthalmology,General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12886-016-0207-3

Reference26 articles.

1. Deloitte Access Economics. Eyes on the future: A clear outlook on age-related macular degeneration. Macular Degeneration Foundation. 2011. Available at www.mdfoundation.com.au/LatestNews/MDFoundationDeloitteAccessEconomicsReport2011.pdf . Accessed 15 March 2016.

2. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31.

3. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, et al. ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR Study. Ophthalmology. 2009;116:57–65.

4. Novartis Pharmaceuticals Australia. Lucentis Australian Prescribing Information. 2011.

5. Eldem MB, Bartz-Schmidt KU, Schlingemann RO, Guymer R, Axer-Siegel R, on behalf of the EXCITE study group. Visual acuity response profiles in patients with neovascular age-related macular degeneration treated quarterly with ranibizumab in the EXCITE trial. Invest Ophthalmol Vis Sci. 2009;50:2374.

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of residual retinal fluid on treatment outcomes in neovascular age-related macular degeneration;British Journal of Ophthalmology;2024-07-20

2. The effect of four loading intravitreal aflibercept injections on macular fluid in treatment-naïve neovascular age-related macular degeneration;Eye;2024-07-06

3. Artificial intelligence for retinal diseases;Asia-Pacific Journal of Ophthalmology;2024-07

4. Clinical and Imaging Biomarkers Associated with Outer Retinal Atrophy Onset in Exudative Age-Related Macular Degeneration: A Real-Word Prospective Study;Ophthalmology and Therapy;2024-03-06

5. One-year outcome of brolucizumab for neovascular age-related macular degeneration in Japanese patients;Scientific Reports;2024-01-30